Study on the efficacy and safety of sulbactam/ampicillin in perforative peritonitis

Abstract

A combined β-lactamase inhibitor plus penicillin preparation, sulbactam sodium/ampicillin sodium (UNASYN^®-S), was used to treat perforative peritonitis, and the following results were obtained. Of 36 patients who were enrolled in the study, efficacy was evaluated in 22 patients, and their peritonitis was secondary to appendiceal perforation in 11 cases, duodenal perforation in 9 cases, gastric ulcer perforation in 1 case, and traumatic small intestinal perforation in 1 case. The overall efficacy rate was 90.9%(20/22), and the efficacy in the 10 cases in which the pathogens had been isolated and identified was 80.0%(8/10). Assessment of bacteriological response showed that 10 of the 12 pathogens were eradicated. The safety evaluation showed that 1 of the 36 patients enrolled in the study had adverse drug reactions of increases in AST (GOT), ALT (GPT), and ALP values.